Sign In
Buy RCUS
$28.42
-1.31 (-4.41%)
At Close: Jul 24, 2026
Why Arcus Biosciences Just Reversed Its 287% Eight-Month Winning Streak
12:35pm, Friday, 12'th Dec 2025
Arcus Biosciences stock plunged Friday, reversing a nearly 300% gain, after its Gilead Sciences-partnered cancer regimen failed.
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
Arcus Biosciences Announces New Employment Inducement Grants
06:00pm, Tuesday, 09'th Dec 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
Arcus Biosciences, Inc. (RCUS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
02:33pm, Wednesday, 03'rd Dec 2025
Arcus Biosciences, Inc. (RCUS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
04:05pm, Tuesday, 18'th Nov 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patient
Arcus Biosciences President Sells $2 Million in Stock Under Trading Plan
07:57am, Sunday, 02'nd Nov 2025
Juan C. Jaen, the president of Arcus Biosciences (RCUS 2.33%), sold 96,859 shares in multiple open-market transactions on Tuesday and Wednesday, according to an SEC Form 4 filing.
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
11:35pm, Thursday, 30'th Oct 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for
Arcus Biosciences Announces Commencement of Public Offering of Common Stock
04:01pm, Thursday, 30'th Oct 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for
Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Beats Revenue Estimates
06:56pm, Tuesday, 28'th Oct 2025
Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1.27 per share versus the Zacks Consensus Estimate of a loss of $1.33. This compares to a loss of $1 per share a year ago.
Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update
04:05pm, Tuesday, 28'th Oct 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
Arcus Biosciences (RCUS) Surges 7.5%: Is This an Indication of Further Gains?
06:26am, Tuesday, 28'th Oct 2025
Arcus Biosciences (RCUS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price in
Arcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Recommendation of “Moderate Buy” by Brokerages
01:31am, Sunday, 26'th Oct 2025
Arcus Biosciences, Inc. (NYSE: RCUS - Get Free Report) has been assigned an average rating of "Moderate Buy" from the ten ratings firms that are presently covering the company, MarketBeat reports. One
Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia
07:00pm, Sunday, 19'th Oct 2025
TOKYO & HAYWARD, Calif.--(BUSINESS WIRE)--Taiho Pharmaceutical Co., Ltd. (“Taiho”) and Arcus Biosciences, Inc. (NYSE:RCUS, “Arcus”) announced that Taiho exercised its option to develop and, if
Arcus Biosciences: Refusing To Let The TIGIT Story Die, And Finding Potential Niches In Huge Markets
11:18am, Thursday, 16'th Oct 2025
Arcus Biosciences (RCUS) boasts a diverse, promising pipeline with key candidates like domvanalimab, casdatifan, and quemliclustat advancing in pivotal trials. Recent data from RCUS's EDGE-Gastric tri
Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months
10:33am, Monday, 13'th Oct 2025
On Sunday, Arcus Biosciences Inc. (NYSE:RCUS) announced the first overall survival results from Arm A1 of the Phase 2 EDGE-Gastric study in patients with locally advanced, unresectable, or metastatic
